Active	Status	Sponsor type	Region	Phase	Filter
4 Active 10 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
apabetalone (RVX 208) / Resverlogix
NCT04894266: An Open-Label Study of Apabetalone in Covid Infection	Terminated	2/3	1	Canada	Apabetalone, Standard of care	Resverlogix Corp	COVID-19 Infection	06/22	06/22
NCT06590324: A Study of Apabetalone in Subjects With Long -COVID	Recruiting	2/3	200	RoW	Apabetalone, RVX000222	Resverlogix Corp	Post-Acute COVID-19 Syndrome	12/25	03/26
APPROACH-2, NCT04915300: Apabetalone for Pulmonary Arterial Hypertension	Not yet recruiting	2	72	Canada	Apabetalone, Placebo	Laval University, Canadian Institutes of Health Research (CIHR), Resverlogix Corp	Pulmonary Arterial Hypertension	03/25	03/25
NCT03160430: A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis	Not yet recruiting	1/2	44	NA	apabetalone, RVX000222, RVX-208, Placebos, Matching placebo	Resverlogix Corp	Kidney Failure, Chronic	11/26	11/26
NexVas AD (apoA-I enhancing therapy) / Resverlogix
No trials found
RVX-408 / Resverlogix
No trials found
RVX 297 / Resverlogix, Zenith Capital Corp
No trials found
RVX-2135 / Resverlogix
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
apabetalone (RVX 208) / Resverlogix
NCT04894266: An Open-Label Study of Apabetalone in Covid Infection	Terminated	2/3	1	Canada	Apabetalone, Standard of care	Resverlogix Corp	COVID-19 Infection	06/22	06/22
NCT06590324: A Study of Apabetalone in Subjects With Long -COVID	Recruiting	2/3	200	RoW	Apabetalone, RVX000222	Resverlogix Corp	Post-Acute COVID-19 Syndrome	12/25	03/26
APPROACH-2, NCT04915300: Apabetalone for Pulmonary Arterial Hypertension	Not yet recruiting	2	72	Canada	Apabetalone, Placebo	Laval University, Canadian Institutes of Health Research (CIHR), Resverlogix Corp	Pulmonary Arterial Hypertension	03/25	03/25
NCT03160430: A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis	Not yet recruiting	1/2	44	NA	apabetalone, RVX000222, RVX-208, Placebos, Matching placebo	Resverlogix Corp	Kidney Failure, Chronic	11/26	11/26
NexVas AD (apoA-I enhancing therapy) / Resverlogix
No trials found
RVX-408 / Resverlogix
No trials found
RVX 297 / Resverlogix, Zenith Capital Corp
No trials found
RVX-2135 / Resverlogix
No trials found